Menu
1. Durée et type d'antiagrégation plaquettaire post-sca : less is more ?
2. POTENTIAL CONFLICTS OF INTEREST
3. DUAL ANTIPLATELET THERAPY DURATION AFTER PCI WITH DRUG-ELUTING STENTS
4. MAJOR BLEEDING INCIDENCE AND PROGNOSTIC IMPLICATIONS
5. ANTIPLATELET THERAPY AFTER ACS
6. ASPIRIN-FREE STRATEGIES AFTER PCI/ACS AVAILABLE CLINICAL EVIDENCE
7. ASPIRIN-FREE STRATEGY IN HIGH-RISK PATIENTS TWILIGHT TRIAL
8. ETUDE TICO
9. TICO TRIAL STUDY DESIGN
10. TICO TRIAL METHODS
11. TICO TRIAL KEY INCLUSION/EXCLUSION CRITERIA
12. TICO TRIAL PATIENT FLOW CHART
13. TICO TRIAL PATIENT BASELINE CHARACTERISTICS
14. TICO TRIAL PRIMARY ENDPOINT
15. TICO TRIAL INDIVIDUAL COMPONENTS OF PRIMARY ENDPOINT
16. TICO TRIAL INDIVIDUAL COMPONENTS OF PRIMARY ENDPOINT
17. TICO TRIAL CONCLUSIONS
18. TICO TRIAL LIMITATIONS
19. TICO TRIAL MY PERSONAL PERSPECTIVE
20. PROLONGED DAPT AFTER ACS PEGASUS-TIMI 54 TRIAL
21. TICO TRIAL MY PERSONAL PERSPECTIVE
22. MERCI
23. DUREE ET TYPE D'ANTIAGREGATION PLAQIETTAIRE POST-SCA : LESS IS MORE ?
Durée et type d'antiagrégation plaquettaire post-sca, Dr Juan Iglesias, 04.08.20
Resources
Here are some useful links and documents:
Title
Title
Title
FINISH
SUBMIT
NEXT
PREV
Submit All
